Long-term outcomes for patients with Hodgkin lymphoma at increased risk of progression or relapse

References

• Glimelius I, Ekberg S, Jerkeman M, et al. Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics. Am J Hematol. 2015;90(12):1128–1134.
   PubMed Web of Science ®Google Scholar
• LaCasce AS. Treating Hodgkin lymphoma in the new millennium: relapsed and refractory disease. Hematol Oncol. 2019;37(S1):87–91.
   PubMedGoogle Scholar
• Schmitz N, Pfistner B, Sextro M, et al.; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–2071.
   PubMed Web of Science ®Google Scholar
• Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–652.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339(21):1506–1514.
   PubMed Web of Science ®Google Scholar
• Cosset JM, Henry-Amar M, Meerwaldt JH, et al. The EORTC trials for limited stage Hodgkin’s disease. The EORTC lymphoma cooperative group. Eur J Cancer. 1992;28a(11):1847–1850.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. Hodgkin lymphoma. Version 2.2022. 2022—[cited 2022 Jun 8]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf.
   Google Scholar
• Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(5):704–715.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al.; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC lymphoma group controlled clinical trials: 1964–1987. Blood. 1989;73(1):47–56.
   PubMed Web of Science ®Google Scholar
• Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med. 2007;357(19):1916–1927.
   PubMed Web of Science ®Google Scholar
• Diehl V, Stein H, Hummel M, et al. Hodgkin’s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003;2003(1):225–247.
   Google Scholar
• Moccia AA, Donaldson J, Chhanabhai M, et al. International prognostic score in advanced-stage Hodgkin’s lymphoma: altered utility in the modern era. J Clin Oncol. 2012;30(27):3383–3388.
   PubMed Web of Science ®Google Scholar
• Lynch RC, Advani RH. Risk-adapted treatment of advanced Hodgkin lymphoma with PET-CT. Am Soc Clin Oncol Educ Book. 2016;35:e376–e385.
   PubMedGoogle Scholar
• Spinner MA, Advani RH. Risk-adapted therapy for advanced-stage Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2018;2018(1):200–206.
   PubMedGoogle Scholar
• Lim SH, Johnson PWM. Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood. 2018;131(15):1679–1688.
   PubMed Web of Science ®Google Scholar
• André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786–1794.
   PubMed Web of Science ®Google Scholar
• Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol. 2002;20(1):221–230.
   PubMed Web of Science ®Google Scholar
• Martínez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin’s lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol. 2013;24(9):2430–2434.
   PubMed Web of Science ®Google Scholar
• Hahn T, McCarthy PL, Carreras J, et al. Simplified validated prognostic model for progression-free survival after autologous transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2013;19(12):1740–1744.
   PubMed Web of Science ®Google Scholar
• Hahn T, Benekli M, Wong C, et al. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin’s disease. Bone Marrow Transplant. 2005;35(6):557–566.
   PubMed Web of Science ®Google Scholar
• Smith SD, Moskowitz CH, Dean R, et al. Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J Haematol. 2011;153(3):358–363.
   PubMed Web of Science ®Google Scholar
• Brice P, Bouabdallah R, Moreau P, et al.; Société Française de Greffe de Moëlle. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transplant. 1997;20(1):21–26.
   PubMed Web of Science ®Google Scholar
• Lohri A, Barnett M, Fairey RN, et al. Outcome of treatment of first relapse of Hodgkin’s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood. 1991;77(10):2292–2298.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–1862.
   PubMed Web of Science ®Google Scholar
• Bröckelmann PJ, Müller H, Casasnovas O, et al. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2017;28(6):1352–1358.
   PubMed Web of Science ®Google Scholar
• Engert A, Schiller P, Josting A, et al.; German Hodgkin’s Lymphoma Study Group. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the. J Clin Oncol. 2003;21(19):3601–3608.
   PubMed Web of Science ®Google Scholar
• Sasse S, Bröckelmann PJ, Goergen H, et al. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin study group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017;35(18):1999–2007.
   PubMed Web of Science ®Google Scholar
• Fermé C, Thomas J, Brice P, et al.; Groupe d’Étude des Lymphomes de l’Adulte. ABVD or BEACOPP(baseline) along with involved-field radiotherapy in early-stage Hodgkin lymphoma with risk factors: results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d’Étude des Lymphomes de l’Adulte (GELA) H9-U intergroup randomised trial. Eur J Cancer. 2017;81:45–55.
   PubMed Web of Science ®Google Scholar
• Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199–4206.
   PubMed Web of Science ®Google Scholar
• Weil CR, Qian Y, Von Eyben R, et al. Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation. Leuk Lymphoma. 2020;61(10):2428–2434.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Arnason JE, LaCasce AS, et al. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. 2019;134(7):606–613.
   PubMed Web of Science ®Google Scholar
• Park SI, Shea TC, Olajide O, et al. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma. Blood Adv. 2020;4(11):2548–2555.
   PubMed Web of Science ®Google Scholar
• Fornecker LM, Lazarovici J, Aurer I, et al.; LYSA-FIL-EORTC Intergroup. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial. J Clin Oncol. 2022;40:Jco2101281.
   Google Scholar
• Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–4554.
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Kreissl S, Goergen H, et al. Intensive treatment strategies in advanced-stage Hodgkin’s lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018;5(10):e462–e473.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin study group. J Clin Oncol. 2011;29(32):4234–4242.
   PubMed Web of Science ®Google Scholar
• Carde P, Karrasch M, Fortpied C, et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score ≥3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial. J Clin Oncol. 2016;34(17):2028–2036.
   PubMed Web of Science ®Google Scholar
• Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016;34(11):1175–1181.
   PubMed Web of Science ®Google Scholar
• Federico M, Luminari S, Iannitto E, et al.; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009;27(5):805–811.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Plütschow A, Kobe C, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(2):223–234.
   PubMed Web of Science ®Google Scholar
• Engert A, Haverkamp H, Kobe C, et al.; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–1799.
   PubMed Web of Science ®Google Scholar
• Engert A, Goergen H, Markova J, et al. Reduced-intensity chemotherapy in patients with advanced-stage Hodgkin lymphoma: updated results of the open-label, international, randomised phase 3 HD15 trial by the German Hodgkin study group. HemaSphere. 2017;1(1):e5.
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–2429.
   PubMed Web of Science ®Google Scholar
• Trotman J, Fosså A, Federico M, et al. Response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial: longer follow up confirms efficacy of de-escalation after a negative interim PET scan (CRUK/07/033). Hematol Oncol. 2017;35(S2):65–67.
   Google Scholar
• Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin study group. Lancet. 2017;390(10114):2790–2802.
   PubMed Web of Science ®Google Scholar
• Casasnovas RO, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20(2):202–215.
   PubMed Web of Science ®Google Scholar
• Connors JM, Jurczak W, Straus DJ, et al.; ECHELON-1 Study Group. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–344.
   PubMed Web of Science ®Google Scholar
• Straus DJ, Długosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021;8(6):e410–e421.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Connors JM, Radford JA, et al. First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: an updated analysis of ECHELON-1. J Clin Oncol. 2022;40(16_Suppl):7503–7503.
   Web of Science ®Google Scholar
• Eichenauer DA, Plütschow A, Kreissl S, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin study group. Lancet Oncol. 2017;18(12):1680–1687.
   PubMed Web of Science ®Google Scholar
• Damaschin C, Goergen H, Kreissl S, et al. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin study group. Leukemia. 2022;36(2):580–582.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Rossi A, Patti C, et al. Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL/FIL HD0607 trial. J Clin Oncol. 2020;38(33):3905–3913.
   PubMed Web of Science ®Google Scholar
• Kreissl S, Goergen H, Buehnen I, et al.; German Hodgkin Study Group. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021;8(6):e398–e409.
   PubMed Web of Science ®Google Scholar
• Sirohi B, Cunningham D, Powles R, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol. 2008;19(7):1312–1319.
   PubMed Web of Science ®Google Scholar
• Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(10):1065–1072.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
   PubMed Web of Science ®Google Scholar
• Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–1566.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254–267.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Chatzidimitriou C, Asimakopoulos JV, et al. Immunotherapy in Hodgkin lymphoma: present status and future strategies. Cancers. 2019;11(8):1071.
   PubMed Web of Science ®Google Scholar
• Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428–1439.
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–1294.
   PubMed Web of Science ®Google Scholar
• Ansell S, Bröckelmann P, von Keudell G, et al. HL-398: five-year overall survival from the CheckMate 205 study of nivolumab for relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). Clin Lymphoma Myeloma Leuk. 2021;21:S373–S374.
   Web of Science ®Google Scholar
• Chen R, Zinzani PL, Fanale MA, et al.; KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–2132.
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144–1153.
   PubMed Web of Science ®Google Scholar
• Armand P, Zinzani PLL, Lee HJ, et al. Five-Year follow-up of keynote-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). Blood. 2021;138(Suppl 1):1366–1366.
   Google Scholar
• Wu J, Song Y, Chen X, et al. Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: extended follow-up of the multicenter, single-arm, phase 2 study. Int J Cancer. 2022;150(6):984–992.
   PubMed Web of Science ®Google Scholar
• Song Y, Gao Q, Zhang H, et al. Tislelizumab for relapsed/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis. Clin Cancer Res. 2022;28(6):1147–1156.
   PubMed Web of Science ®Google Scholar
• Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6(1):e12–e19.
   PubMed Web of Science ®Google Scholar
• Su H, Song Y, Jiang W, et al. Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study. J Clin Oncol. 2020;38(15_Suppl):8034–8034.
   Web of Science ®Google Scholar
• Armand P, Chen YB, Redd RA, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134(1):22–29.
   PubMed Web of Science ®Google Scholar
• Bröckelmann PJ, Goergen H, Keller U, et al. Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin study group NIVAHL trial. JAMA Oncol. 2020;6(6):872–880.
   PubMed Web of Science ®Google Scholar
• Ramchandren R, Domingo-Domènech E, Rueda A, et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study. J Clin Oncol. 2019;37(23):1997–2007.
   PubMed Web of Science ®Google Scholar
• Stephens DM, Li H, Schöder H, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019;134(15):1238–1246.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. 2018;36(5):454–462.
   PubMed Web of Science ®Google Scholar
• Dann EJ, Bairey O, Bar-Shalom R, et al. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients. Br J Haematol. 2017;178(5):709–718.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746–3752.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Haverkamp H, Lohri A, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPP(escalated) alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin study group. Lancet Oncol. 2017;18(4):454–463.
   PubMed Web of Science ®Google Scholar
• Camus V, Jardin F. Cell-Free DNA for the management of classical Hodgkin lymphoma. Pharmaceuticals. 2021;14(3):207.
   Web of Science ®Google Scholar
• Camus V, Viennot M, Lequesne J, et al. Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study. Haematologica. 2021;106(1):154–162.
   PubMed Web of Science ®Google Scholar
• Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood. 2018;131(22):2413–2425.
   PubMed Web of Science ®Google Scholar
• Viviani S, Mazzocchi A, Pavoni C, et al. Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy. Hematol Oncol. 2020;38(4):501–508.
   PubMed Web of Science ®Google Scholar
• Mettler J, Müller H, Voltin CA, et al. Metabolic tumour volume for response prediction in advanced-stage Hodgkin lymphoma. J Nucl Med. 2019;60(2):207–211.
   Web of Science ®Google Scholar
• Allen PB, Savas H, Evens AM, et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood. 2021;137(10):1318–1326.
   PubMed Web of Science ®Google Scholar
• Herrera AF. A phase III, randomized study of nivolumab (Opdivo) plus AVD or brentuximab vedotin (Adcetris) plus AVD in patients (age ≥ 12 years) with newly diagnosed advanced stage classical Hodgkin lymphoma. ClinicalTrials.gov. 2022—[cited 2022 Jun 8; 2022 Jun 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT03907488.
   Google Scholar
• Bartlett NL, Herrera AF, Domingo-Domenech E, et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136(21):2401–2409.
   PubMed Web of Science ®Google Scholar
• Ramos CA, Grover NS, Beaven AW, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38(32):3794–3804.
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, André M, Gastinne T, et al. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica. 2018;103(5):840–848.
   PubMed Web of Science ®Google Scholar
• Mohty R, Dulery R, Bazarbachi AH, et al. Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies. Blood Cancer J. 2021;11(7):126.
   PubMed Web of Science ®Google Scholar